As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

If approved, Dupixent would be the first and only targeted medicine to treat bullous pemphigoid in the U.S ... as a chronic debilitating and relapsing skin condition, BP is driven by type 2 ...

Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

Bullous pemphigoid (BP), which has no FDA-approved targeted therapies, leads to reddening of the skin and the formation of painful and intensely itchy chronic lesions and blisters, in some cases ...

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

First up is the ADEPT study in bullous pemphigoid (BP), a rare skin condition that leads to ... hard-to-treat disease in which the standard of care is oral and topical corticosteroids and ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...